(Q41409507)

30 September 2017

1 reference

title

Prostate-specific antigen, clinical use and staging: an overview (English)

1 reference

30 September 2017

Stenman UH

1

1 reference

30 September 2017

publication date

1 March 1997

1 reference

British Journal of Urology

30 September 2017

published in

1 reference

30 September 2017

volume

79 Suppl 1

1 reference

30 September 2017

page(s)

53-60

1 reference

Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer

30 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.1997.TB00802.X

Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.1997.TB00802.X

Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.1997.TB00802.X

The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.1997.TB00802.X

Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.1997.TB00802.X

Prostate-specific antigen: establishment of the reference range for the clinically normal prostate gland and the effect of digital rectal examination, ejaculation, and time on serum concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.1997.TB00802.X

Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.1997.TB00802.X

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.1997.TB00802.X

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.1997.TB00802.X

Screening for prostate cancer. A decision analytic view

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.1997.TB00802.X

Long-term survival among men with conservatively treated localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.1997.TB00802.X

Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.1997.TB00802.X

Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.1997.TB00802.X

Ejaculation increases the serum prostate-specific antigen concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.1997.TB00802.X

Prostate-Specific antigen expression by various tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.1997.TB00802.X

10.1111/J.1464-410X.1997.TB00802.X

21 January 2018

Identifiers

DOI

1 reference

30 September 2017

1 reference